Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study

The modified dose (MD) regimen of pembrolizumab (2 mg/kg or 100 mg every 3 weeks) is an alternative option to reduce the financial burden resulting from the extremely high cost of the standard dose (SD) regimen (200 mg every 3 weeks). However, the clinical effectiveness and prognostic outcomes have...

Descripción completa

Detalles Bibliográficos
Autores principales: To, Sheng-Yin, Kao, Li-Ting, Shih, Jui-Hu, Li, I-Hsun, Huang, Tsai-Wang, Tsai, Chen-Liang, Chian, Chih-Feng, Ho, Ching-Liang, Chang, Ping-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141635/
https://www.ncbi.nlm.nih.gov/pubmed/35627534
http://dx.doi.org/10.3390/ijerph19105999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141635/
https://www.ncbi.nlm.nih.gov/pubmed/35627534
http://dx.doi.org/10.3390/ijerph19105999

Ejemplares similares